Skip to main content
SpringerLink
Log in

How to handle low-molecular-weight heparins in patients with decreased renal function: an open issue

  • IM - Commentary
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Szczech LA, Lazar IL (2004) Projecting the United States ESRD population: issues regarding treatment of patients with ESRD. Kidney Int Suppl 90:S3–S7

    Article  PubMed  Google Scholar 

  2. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S

    Article  PubMed  CAS  Google Scholar 

  3. Hirsh J, Anand SS, Halperin JL, Fuster V (2001) Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103:2994

    PubMed  CAS  Google Scholar 

  4. Perry DJ (1994) Antithrombin and its inherited deficiencies. Blood Rev 8:37

    Article  PubMed  CAS  Google Scholar 

  5. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688

    Article  PubMed  CAS  Google Scholar 

  6. Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood 79:1

    PubMed  CAS  Google Scholar 

  7. Warkentin TE, Levine MN, Hirsh J et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330

    Article  PubMed  CAS  Google Scholar 

  8. Bhandari M, Hirsh J, Weitz JI et al (1998) The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 80:413

    PubMed  CAS  Google Scholar 

  9. Monreal M, Lafoz E, Olive A et al (1994) Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71:7

    PubMed  CAS  Google Scholar 

  10. van Dongen CJ, van den Belt AG, Prins, MH, Lensing, AW (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev CD001100

  11. Schraibman IG, Milne AA, Royle EM (2001) Home versus in-patient treatment for deep vein thrombosis (Cochrane Review). Cochrane Database Syst Rev 2:CD003076

  12. White RH, Ginsberg JS (2003) Low-molecular-weight heparins: are they all the same? Br J Haematol 121:12

    Article  PubMed  CAS  Google Scholar 

  13. Nagge J, Crowther M, Hirsh J (2002) Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162:2605

    Article  PubMed  Google Scholar 

  14. Thorevska N, Amoateng-Adjepong Y, Sabahi R et al (2004) Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 125:856

    Article  PubMed  CAS  Google Scholar 

  15. Monreal M, Falga C, Valle R et al (2006) Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 119:1073

    Article  PubMed  Google Scholar 

  16. Siguret V, Pautas E, Fevrier M et al (2000) Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84:800

    PubMed  CAS  Google Scholar 

  17. Chow SL, Zammit K, West K et al (2003) Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 43:586

    PubMed  CAS  Google Scholar 

  18. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673

    PubMed  CAS  Google Scholar 

  19. Lim W Low-Molecular-Weight Heparin in Patients with Chronic Renal Insufficiency. Intern Emerg Med doi:10.1007/s11739-008-0164-9

Download references

Conflict of interest statement

The authors declare that they have no conflict of interest related to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Section of Nephrology, University of Foggia, Viale Luigi Pinto, 1, 71100, Foggia, Italy

    Giuseppe Stefano Netti & Loreto Gesualdo

  2. Department of Biomedical Sciences, Section of Medical Genetics, University of Foggia, Foggia, Italy

    Maurizio Margaglione

Authors
  1. Giuseppe Stefano Netti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maurizio Margaglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Loreto Gesualdo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Loreto Gesualdo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Netti, G.S., Margaglione, M. & Gesualdo, L. How to handle low-molecular-weight heparins in patients with decreased renal function: an open issue. Intern Emerg Med 3, 307–309 (2008). https://doi.org/10.1007/s11739-008-0195-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-008-0195-2

Search

Navigation